Compare Stocks: QURE, IOVA, KNSA, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$9.57 -35.4%	$11.35	$1.76 ▼ $15.37	$4.31B	0.76	15.54 million shs	29.64 million shs
KNSA Kiniksa Pharmaceuticals International	$97.66 +2.6%	$78.54	$36.56 ▼ $97.05	$7.55B	0.04	694,352 shs	270,316 shs
QURE uniQure	$25.64 +2.7%	$35.50	$8.73 ▼ $69.99	$1.78B	1.06	2.39 million shs	391,829 shs
RYTM Rhythm Pharmaceuticals	$93.62 +1.8%	$97.96	$74.50 ▼ $122.20	$6.40B	2.01	745,962 shs	141,771 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	+1.58%	+1.30%	+34.76%	+215.78%	+576.26%
KNSA Kiniksa Pharmaceuticals International	+6.70%	+19.42%	+25.07%	+21.71%	+141.39%
QURE uniQure	+2.84%	+10.05%	-36.15%	-40.82%	-64.33%
RYTM Rhythm Pharmaceuticals	-0.23%	+3.78%	-6.69%	-13.02%	-18.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$9.57 -35.4%	$11.35	$1.76 ▼ $15.37	$4.31B	0.76	15.54 million shs	29.64 million shs
KNSA Kiniksa Pharmaceuticals International	$97.66 +2.6%	$78.54	$36.56 ▼ $97.05	$7.55B	0.04	694,352 shs	270,316 shs
QURE uniQure	$25.64 +2.7%	$35.50	$8.73 ▼ $69.99	$1.78B	1.06	2.39 million shs	391,829 shs
RYTM Rhythm Pharmaceuticals	$93.62 +1.8%	$97.96	$74.50 ▼ $122.20	$6.40B	2.01	745,962 shs	141,771 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	+1.58%	+1.30%	+34.76%	+215.78%	+576.26%
KNSA Kiniksa Pharmaceuticals International	+6.70%	+19.42%	+25.07%	+21.71%	+141.39%
QURE uniQure	+2.84%	+10.05%	-36.15%	-40.82%	-64.33%
RYTM Rhythm Pharmaceuticals	-0.23%	+3.78%	-6.69%	-13.02%	-18.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.71	Moderate Buy	$13.20	38.00% Upside
KNSA Kiniksa Pharmaceuticals International	2.78	Moderate Buy	$98.43	0.78% Upside
QURE uniQure	2.76	Moderate Buy	$53.25	107.72% Upside
RYTM Rhythm Pharmaceuticals	2.77	Moderate Buy	$142.50	52.21% Upside

Current Analyst Ratings Breakdown

Latest QURE, IOVA, KNSA, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C-)
10/28/2026	KNSA Kiniksa Pharmaceuticals International	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$90.00 ➝ $101.00
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$99.00 ➝ $102.00
10/28/2026	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$87.00 ➝ $110.00
10/26/2026	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/16/2026	RYTM Rhythm Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	QURE uniQure	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$27.00 ➝ $48.00
10/15/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$146.00 ➝ $145.00
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/12/2026	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00

(Data available from 10/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$263.50M	16.44	N/A	N/A	$1.76 per share	5.43
KNSA Kiniksa Pharmaceuticals International	$677.56M	11.25	$1.01 per share	96.67	$7.44 per share	13.13
QURE uniQure	$18.67M	95.23	N/A	N/A	$3.19 per share	8.04
RYTM Rhythm Pharmaceuticals	$189.76M	33.81	N/A	N/A	$2.08 per share	45.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	99.81	47.18	N/A	9.59%	13.65%	10.09%	N/A
QURE uniQure	-$198.97M	-$4.01	N/A	N/A	N/A	-1,350.73%	-111.96%	-29.01%	11/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest QURE, IOVA, KNSA, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	QURE uniQure	-$0.9152	N/A	N/A	N/A	$6.18 million	N/A
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0850	N/A	N/A	N/A	$115.53 million	N/A
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7101	N/A	N/A	N/A	$85.48 million	N/A
10/27/2026	Q3 2026	KNSA Kiniksa Pharmaceuticals International	$0.3710	$0.56	+$0.1890	$0.56	$260.66 million	$285.97 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/29/2026	Q2 2026	QURE uniQure	-$0.8223	-$1.22	-$0.3977	-$1.22	$5.45 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
QURE uniQure	0.15	10.01	10.01
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
KNSA Kiniksa Pharmaceuticals International	53.95%
QURE uniQure	78.83%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
KNSA Kiniksa Pharmaceuticals International	51.98%
QURE uniQure	4.65%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
KNSA Kiniksa Pharmaceuticals International	366	78.02 million	37.47 million	Optionable
QURE uniQure	221	69.37 million	66.14 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

QURE, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

October 27 at 11:06 AM | zacks.com

Rhythm Pharmaceuticals (RYTM) Projected to Post Earnings on Tuesday

October 27 at 6:55 AM | marketbeat.com

Rhythm Pharmaceuticals, Inc. (RYTM) - What Are Brokerages Saying About This Stock?

October 25, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages

October 25, 2026 | marketbeat.com

William Blair initiates coverage of Rhythm Pharmaceuticals at outperform

October 22, 2026 | msn.com

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 21, 2026 | globenewswire.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with 67% Upside Potential

October 19, 2026 | directorstalkinterviews.com

176,882 Rhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Assenagon Asset Management S.A.

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Stock Sold by Aspiriant LLC

October 18, 2026 | marketbeat.com

JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

October 15, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Has Lowered Expectations for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

October 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. Announces Commercial Launch of IMCIVREE® (Setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 14, 2026 | marketscreener.comM

Rhythm launches IMCIVREE in Japan

October 14, 2026 | grafa.comG

Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity

October 14, 2026 | rttnews.com

HC Wainwright Has Positive Outlook for RYTM Q3 Earnings

October 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 13, 2026 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

October 13, 2026 | zacks.com

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies

October 13, 2026 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 52.99% Upside Potential

October 12, 2026 | directorstalkinterviews.com

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

October 9, 2026 | finance.yahoo.com

RBC raises target for Rhythm Pharmaceuticals stock to USD 159

October 8, 2026 | ad-hoc-news.deA

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$9.56 -5.25 (-35.42%)

As of 11:16 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$97.66 +2.48 (+2.61%)

As of 11:15 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

uniQure NASDAQ:QURE

$25.64 +0.67 (+2.66%)

As of 11:16 AM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Rhythm Pharmaceuticals NASDAQ:RYTM

$93.62 +1.65 (+1.79%)

As of 11:16 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, IOVA, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, IOVA, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Kiniksa Pharmaceuticals International NASDAQ:KNSA

uniQure NASDAQ:QURE

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QURE, IOVA, KNSA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QURE, IOVA, KNSA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QURE, IOVA, KNSA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE, IOVA, KNSA, and RYTM Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Kiniksa Pharmaceuticals International NASDAQ:KNSA

uniQure NASDAQ:QURE

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools